ient with HLA-B27-associated spondyloarthropathy and HIV infection [43].
In contrast to the results mentioned above has been published a randomized, double-blind, placebo-controlled trial performed on 83 patients to which 400 mg HCQ (n = 42) or placebo (n = 41) were administered for 48 w